Heparinase I

Drug Profile

Heparinase I

Alternative Names: Heparin eliminase; Heparin lyase; Heparinase; Neutralase

Latest Information Update: 24 Sep 2003

Price : $50

At a glance

  • Originator IBEX Technologies
  • Developer BioMarin Pharmaceutical; Montreal Heart Institute
  • Class Coagulants; Polysaccharide lyases
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Blood coagulation disorders

Most Recent Events

  • 22 Sep 2003 Discontinued - Phase-III for Coagulation disorders in USA (IV)
  • 22 Sep 2003 Discontinued - Phase-III for Coagulation disorders in Germany (IV)
  • 22 Sep 2003 Discontinued - Phase-III for Coagulation disorders in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top